We are proud to welcome you to the fourth edition of the Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2020), that will be held in Lyon, France on December 9-10, 2020.
The purpose of this two-day congress is to foster interactions between pharmaceutical industries, research labs, service providers, technology developers, and clinicians, thereby contributing to the development of innovative strategies against infectious diseases in a multidisciplinary approach.
I4ID2020 will build on the successes of the first three editions, I4ID2017, I4ID2018 & I4ID2019 that counted with the presence of more than 550 participants from different countries representing over 300 organizations and 100 internationally renowned speakers exchanging on immunotherapy and new therapeutic approaches to fight infectious diseases.
The I4ID2020 edition will largely address the current COVID-19 pandemics as well as other infectious diseases. The Scientific Committee has set-up a stimulating program focusing on Detection, Diagnosis, Clinical Trials immunotherapies and Innovative therapeutic approaches to prevent & fight infectious diseases.
The I4ID2020 will include keynote lectures, pitch talks of new innovative projects, industrial talks from pharmaceutical companies and poster presentations.
Moreover, there will be several opportunities for networking, companies to showcase their new products and technologies as well as dedicated time for business partnering, through an online B2B platform.
Are you interested in attending the Immunotherapies & Innovations for Infectious Diseases – I4ID Congress?
We are currently preparing the program of this new edition, we will let you know when it is ready so come back soon to check out our program.
Do you want your company to be visible at the I4ID2020 conference? Check out our sponsors & exhibitors’ opportunities.
The congress will take place at the Amphitheatre Mérieux, in Lyon, France.
Looking forward to welcoming you in December 9-10, 2020 in Lyon.
The Organizing Committee – BIOASTER, Lyonbiopole and MabDesign
The Scientific Committee